{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "JNJ",
  "name": "Johnson & Johnson",
  "url": "https://frontierpicks.com/dossiers/JNJ/",
  "json_url": "https://frontierpicks.com/dossiers/JNJ.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Johnson & Johnson's drug approvals keep coming, but weak medical devices and $1.36 per share of 2027 deal dilution leave the shares more likely to lag the S&P 500. The 8 December 2026 business review and January 2027 guidance settle it.",
  "invalidation_trigger": "A weekly close above $290, over the 2026-11-12 intraday high of $286.08 and above every cited consensus target, which would show the shares leading; or 2027 adjusted EPS guidance above the 2026 midpoint of $11.10.",
  "catalyst_date": "2026-11-19",
  "portfolio": null,
  "pick": null,
  "themes": [
    "oncology-immunology",
    "medtech-diagnostics",
    "m-and-a-special-situations"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "California Jury Hits J&J With $34M Talc Verdict in Latest Mesothelioma Trial",
      "url": "https://www.law.com/therecorder/2026/11/09/california-jury-hits-jj-with-34m-talc-verdict-in-latest-mesothelioma-trial/",
      "date": "2026-11-09"
    },
    {
      "title": "J&J Tells FDA It Approves Of Yearly Talc Testing, Proposes Standards",
      "url": "https://mealeys.com/mealeys/mealeys-asbestos/articles/2549453",
      "date": "2026-11-12"
    },
    {
      "title": "curetoday.com",
      "url": "https://www.curetoday.com/view/fda-approves-rybrevant-faspro-for-advanced-head-and-neck-cancer",
      "date": "2026-11-06"
    },
    {
      "title": "Johnson & Johnson's Icotyde Shows Promise in Psoriatic Arthritis Trial, Ticker JNJ",
      "url": "https://gurufocus.com/news/9184016/johnson-johnsons-icotyde-shows-promise-in-psoriatic-arthritis-trial-ticker-jnj",
      "date": null
    },
    {
      "title": "MarketBeat",
      "url": "https://www.marketbeat.com/instant-alerts/price-johnson-johnson-nyse-jnj-stock-jumps-2-whats-next-2026-11-09/",
      "date": "2026-11-09"
    },
    {
      "title": "Johnson & Johnson (JNJ) Stock Price, News, Quote & History",
      "url": "https://finance.yahoo.com/quote/JNJ/",
      "date": null
    },
    {
      "title": "Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight",
      "url": "https://wtop.com/national/2026/07/johnson-johnson-proposes-5-5-billion-talc-settlement-to-end-marathon-legal-fight/",
      "date": null
    },
    {
      "title": "Contract Pharma",
      "url": "https://www.contractpharma.com/breaking-news/fda-approves-jjs-rybrevant-faspro-with-halozymes-enhanze-for-head-and-neck-cancer/",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 sales rose 5.9% reported and 6.0% operationally to $25.4 billion; adjusted EPS was $2.59, down 7.5% from a year earlier.",
      "source": "Third-quarter 2026 earnings release (8-K Exhibit 99.1)",
      "as_of": "2026-10-13"
    },
    {
      "claim": "Innovative Medicine sales were $16.757 billion, up 7.9% operationally; MedTech sales were $8.642 billion, up 2.5% operationally, with international MedTech up 0.1%.",
      "source": "Third-quarter 2026 earnings release and call",
      "as_of": "2026-10-13"
    },
    {
      "claim": "2026 guidance raised to $101.0 billion to $101.4 billion of sales and adjusted EPS of $11.05–11.15, from $100.8 billion to $101.4 billion and $10.96–11.11.",
      "source": "Third-quarter 2026 earnings release",
      "as_of": "2026-10-13"
    },
    {
      "claim": "Management guided to $1.36 per share of combined 2027 EPS dilution from the Firefly Bio acquisition and Sail Biomedicines collaboration, versus $0.64 in 2026.",
      "source": "Third-quarter 2026 earnings call",
      "as_of": "2026-10-13"
    },
    {
      "claim": "FDA granted accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck squamous cell carcinoma, based on a 42% overall response rate in the OrigAMI-4 trial.",
      "source": "CURE, 2026-11-06",
      "as_of": "2026-11-05"
    },
    {
      "claim": "In the Phase 3 ICONIC-PsA 1 trial, 57% of Icotyde patients with qualifying skin involvement reached clear or almost clear skin versus 14% on placebo.",
      "source": "Johnson & Johnson announcement at ACR Convergence 2026; Benzinga 2026-11-09",
      "as_of": "2026-11-07"
    },
    {
      "claim": "A second pivotal Phase 3 study of Caplyta in adults with bipolar I mania met its primary and key secondary endpoints.",
      "source": "Johnson & Johnson announcement, 2026-11-10",
      "as_of": "2026-11-10"
    },
    {
      "claim": "An Alameda County, California jury awarded $34.21 million in a talc mesothelioma case, finding Johnson & Johnson 40% liable, with no punitive damages.",
      "source": "Law.com (The Recorder), 2026-11-09",
      "as_of": "2026-11-09"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-09-27",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-27",
              "filed": "2026-10-21",
              "restated": null,
              "value_musd": 25399,
              "yoy_pct": 5.9
            },
            {
              "end": "2026-06-28",
              "filed": "2026-07-23",
              "restated": null,
              "value_musd": 25310,
              "yoy_pct": 6.6
            },
            {
              "end": "2026-03-29",
              "filed": "2026-04-22",
              "restated": null,
              "value_musd": 24062,
              "yoy_pct": 9.9
            },
            {
              "end": "2025-12-28",
              "filed": "2026-02-11",
              "restated": null,
              "value_musd": 24564,
              "yoy_pct": 9.1
            },
            {
              "end": "2025-09-28",
              "filed": "2025-10-22",
              "restated": null,
              "value_musd": 23993,
              "yoy_pct": 6.8
            },
            {
              "end": "2025-06-29",
              "filed": "2025-07-24",
              "restated": null,
              "value_musd": 23743,
              "yoy_pct": 5.8
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-27",
              "filed": "2026-10-21",
              "restated": null,
              "pct": 68.1
            },
            {
              "end": "2026-06-28",
              "filed": "2026-07-23",
              "restated": null,
              "pct": 68.2
            },
            {
              "end": "2026-03-29",
              "filed": "2026-04-22",
              "restated": null,
              "pct": 66.3
            },
            {
              "end": "2025-12-28",
              "filed": "2026-02-11",
              "restated": null,
              "pct": 67.6
            },
            {
              "end": "2025-09-28",
              "filed": "2025-10-22",
              "restated": null,
              "pct": 69.6
            },
            {
              "end": "2025-06-29",
              "filed": "2025-07-24",
              "restated": null,
              "pct": 67.9
            }
          ]
        },
        "operating_margin": {
          "status": "not reported"
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "value_musd": 34
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "four_quarters_end": "2026-09-27",
          "value_musd": 210,
          "four_quarters_musd": 16095
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "first_end": "2025-12-28",
          "value_musd": 26159
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "first_end": "2025-12-28",
          "value_musd": 5569
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "first_end": "2025-12-28",
          "value_musd": 20590
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "base_end": "2025-09-28",
          "pct": 0.8
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "value_musd": 17228
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "value_musd": 44651,
          "composition": "non-current long-term debt plus short-term borrowings"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "value_musd": -27423
        },
        "deferred_revenue": {
          "status": "not reported"
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "value_musd": 18987
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "value_musd": 15377
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-10-21",
          "value_musd": 81529
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-15",
          "basis_filed": "2026-10-21",
          "value_musd": 687888.9
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-15",
          "basis_filed": "2026-10-21",
          "value_musd": 715311.9
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-15",
          "basis_filed": "2026-10-21",
          "multiple": 7.2
        },
        "ev_ebit": {
          "status": "not available"
        },
        "pe": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-15",
          "basis_filed": "2026-10-21",
          "multiple": 42.7
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-15",
          "basis_filed": "2026-10-21",
          "multiple": 8.4
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-15",
          "basis_filed": "2026-10-21",
          "pct": 3
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": 0.7,
      "days_to_cover": 2,
      "change_pct": -24
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 12947985.86,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 257687.5,
          "sold_usd": 154385117.84,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\n\nJohnson & Johnson's drug pipeline keeps producing approvals and positive trials, but weak medical devices and $1.36 per share of guided 2027 deal dilution make the shares more likely to lag the S&P 500 over the next three months. The Enterprise Business Review on 2026-12-08 and the fourth-quarter report expected in late January 2027 decide whether earnings grow in 2027.\n\nThe rating is Low because the price already sits above analysts' targets while the two numbers behind the caution are unchanged. MedTech grew 2.5% operationally in the third quarter, and management guided on 2026-10-13 to $1.36 per share of 2027 dilution from the Firefly Bio acquisition and the Sail Biomedicines collaboration, against $0.64 in 2026.\n\nThe shares closed at $283.52 on 2026-11-12, above the $279.41 average analyst target Yahoo Finance listed on 2026-11-10 and the $275.92 consensus target MarketBeat reported on 2026-11-09. The market has priced in the drug launches and a clean 2027; further gains depend on what management says about 2027 earnings on 2026-12-08.\n\n## Bull Case\n\n- **Drug growth accelerated despite Stelara.** Innovative Medicine sales rose 7.9% operationally to $16.757 billion in the third quarter, according to the 2026-10-13 release. That beat the second quarter's 6.8% while biosimilar competition to Stelara cut growth by about 6.9 percentage points.\n- **Launch drugs keep compounding.** On the 2026-10-13 call the company reported operational growth of 68.2% for Tremfya, 15.6% for Darzalex and 35.2% for Carvykti.\n- **Rybrevant reaches beyond lung cancer.** The U.S. Food and Drug Administration (FDA) granted accelerated approval to subcutaneous Rybrevant Faspro on 2026-11-05 for recurrent or metastatic head and neck squamous cell carcinoma, CURE reported on 2026-11-06. The approval rests on a 42% overall response rate in the Phase 1b/2 OrigAMI-4 trial.\n- **Icotyde is widening its label.** Johnson & Johnson reported positive Phase 3 ICONIC-PsA 1 results for oral Icotyde (icotrokinra) in psoriatic arthritis on 2026-11-07. In patients with qualifying skin disease, 57% reached clear or almost clear skin against 14% on placebo, Benzinga reported on 2026-11-09.\n- **Caplyta has a second mania win.** The company said on 2026-11-10 that a second pivotal Phase 3 study of Caplyta (lumateperone) in bipolar I mania met its primary and key secondary endpoints. The first study read out positive on 2026-09-21, giving two trials to support a filing in a use where the drug is not yet approved.\n- **Early prostate cancer data look clean.** The company reported on 2026-11-08 that the pasritamig and JNJ-9401 combination produced a 73% prostate-specific antigen response with no grade 3 or higher treatment-related adverse events in a Phase 1 study, Benzinga reported on 2026-11-09.\n- **2026 outlook raised again.** The company guides to $101.0 billion to $101.4 billion of sales and adjusted earnings per share (EPS) of $11.05–11.15, up from $100.8 billion to $101.4 billion and $10.96–11.11 before the 2026-10-13 report.\n\n## Bear Case\n\n- **Medical devices missed again.** MedTech grew 2.5% operationally to $8.642 billion in the third quarter, with international sales up 0.1%, according to the 2026-10-13 release. MedTech head Tim Schmid said on the call that results were \"below expectations previously communicated.\"\n- **2027 earnings carry heavy dilution.** The $1.36 per share of guided 2027 dilution is more than double the 2026 figure. Third-quarter adjusted EPS of $2.59 was already down 7.5% from a year earlier.\n- **Talc verdicts keep coming.** An Alameda County, California jury awarded $34.21 million in a mesothelioma case on 2026-11-09, finding Johnson & Johnson 40% liable, Law.com reported. These asbestos claims sit outside the $5.5 billion ovarian settlement; on 2026-11-12 the company sent the FDA a letter proposing a definition of asbestos in consumer talc and supporting yearly testing, Mealey's reported.\n- **The ovarian settlement is still conditional.** The $5.5 billion proposal from 2026-07-28 covers about 76,000 claims and takes effect only if at least 95% of claimants join, according to AP. The company has published no participation count.\n- **Orthopaedics exit lost its deal route.** Talks to combine DePuy Synthes with Smith & Nephew collapsed over the chief executive role, the Financial Times and Reuters reported on 2026-10-23. The company still targets a separation by mid-2027.\n- **The price is above the targets.** The 2026-11-12 close of $283.52 sits above the $279.41 average target on Yahoo Finance and above Leerink Partners' $272 target, reaffirmed on 2026-10-28.\n- **Senior executives sold shares this year.** Chief executive Joaquin Duato exercised options and sold 123,291 shares at an average $261.17 on 2026-08-13, Innovative Medicine head Jennifer Taubert sold 15,000 shares at $263.36 on 2026-08-17, and MedTech head Tim Schmid sold 33,597 shares at $274.74 on 2026-09-02, according to SEC Form 4 filings.\n\n## Setup & Price Structure\n\nThe shares closed at $283.52 on 2026-11-12 and set a 52-week intraday high of $286.08 in that session. The last close is 0.9% below that high. The 3-month change is 9.4%, measured from the 2026-08-14 close.\n\nThe pipeline run from 2026-11-05 to 2026-11-10 moved the shares from a $272.32 close on 2026-11-05 to $282.11 on 2026-11-09, then $280.78 and $280.41 on the next two sessions, before the 2026-11-12 high. As of the 2026-11-12 close the 50-day moving average stands at $266.72 and the 200-day at $248.00, both well under the price.\n\nThe 52-week closing low was $194.39 on 2025-11-12, so the shares have rerated sharply over the year. The level the case now turns on is the 2026-11-12 high: holding below it into the 2026-12-08 review would fit a lag call, while a sustained move through it would mean investors are paying ahead of the 2027 numbers.\n\n## Catalyst Calendar\n\n- **2026-11-19:** Deadline for talc plaintiffs in federal litigation to show why cases should not be dismissed for lack of admissible causation evidence. The plaintiffs' response bears on the pressure to join the $5.5 billion settlement and its 95% participation condition.\n- **2026-12-08:** Enterprise Business Review for investors, with segment, pipeline and long-term strategy presentations. First detailed look at how management plans to absorb $1.36 per share of 2027 deal dilution and restart MedTech growth; 2027 EPS commentary above $11.10 would undercut the lag call.\n- **~2026-12-15 (est.):** European Commission decision on the Talvey multiple myeloma indication extension. Approval would widen the European label for one of the oncology launches that drive drug growth.\n- **~2027-01-26 (est.):** Fourth-quarter 2026 results and formal 2027 guidance. Shows whether MedTech growth recovers from 2.5% and whether 2027 adjusted EPS guidance clears the 2026 midpoint of $11.10.\n- **~2027-06-30 (est.):** DePuy Synthes orthopaedics separation, targeted by mid-2027. With the Smith & Nephew talks reported collapsed on 2026-10-23, a spin-off is the stated path for removing the slower orthopaedics business.\n\n## What Would Change Our Mind\n\nA weekly close above $290, over the 2026-11-12 intraday high of $286.08 and above every cited consensus target, which would show the shares leading; or 2027 adjusted EPS guidance above the 2026 midpoint of $11.10.\n\n## Correlation Notes\n\nJohnson & Johnson trades with large-cap pharmaceutical and health-care stocks and with defensive sectors; on 2026-11-11, when Benzinga reported cyclicals leading and defensives trailing, the shares closed at $280.41, slightly lower. Talc litigation is a company-specific driver that can move the shares apart from peers. Halozyme supplies the ENHANZE technology in Rybrevant Faspro, per Contract Pharma on 2026-11-06, and Protagonist Therapeutics partners on Icotyde, so news on those drugs reaches both companies. Smith & Nephew and other orthopaedics makers move on news about the DePuy Synthes separation.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-12T23:49:50+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}